Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 4—April 2011
Dispatch

Drug-Resistant Pandemic (H1N1) 2009, South Korea1

Soo Youn Shin, Chun Kang, Jin Gwack, Joon Hyung Kim, Hyun Su Kim, Young A Kang, Ha Gyung Lee, Jin Seok Kim, Jong-Koo Lee, and Sung-Han KimComments to Author 
Author affiliations: Author affiliations: Korea Centers for Disease Control and Prevention, Seoul, South Korea (S.Y. Shin, C. Kang, J. Gwack, J.H. Kim, H.S. Kim, Y.A. Kang, H.G. Lee, J.S. Kim, J.-K. Lee); University of Ulsan College of Medicine, Seoul (S.-H. Kim)

Main Article

Table

Characteristics of 11 patients with oseltamivir-resistant pandemic (H1N1) 2009, South Korea*

Characteristic Value
Median age, y (range) 5 (1–63)
Male sex
 6
No. at high risk for influenza-related complications
<59 mo of age 6
Chronic medical disorders 9
Neurologic 3
Hematologic 3
Metabolic, including diabetes† 2
Pulmonary, including asthma 1
Renal† 1
Cardiovascular, excluding hypertension 0
Hepatic disorder 0
Immunocompromised‡
 5
Median days from symptom onset to viral isolation (range) 2 (0–9)
Median days from symptom onset to development of resistance
 8
No. hospitalized 11
Hospitalization duration, d, median (range) 15 (6–53)
Symptom duration, d, median (range)
 17 (6–22)
No. with respiratory illness related to influenza 11
Viral pneumonia 6
Secondary bacterial pneumonia 2
Secondary bacterial pneumonia and acute respiratory distress syndrome
 1
Reasons for requesting drug-resistance testing
Treatment failure 9
Prolonged viral shedding
 2
No. with co-infections§
 3
Outcome
Cured 8
Died¶ 3

*Specimens were obtained from oropharyngeal (n = 7) and nasopharyngeal (n = 2) swabs, nasopharyngeal washings (n = 1), and brochoalveolar lavage fluid (n = 1).
†One patient had diabetes and chronic renal failure.
‡Patients who had underlying diseases such as HIV infection, malignancy, liver cirrhosis, or chronic renal failure, or patients receiving immunosuppressive treatment.
§Carbapenem-resistant Pseudomonas aeruginosa (patient 3), carbapenem-resistant Acinetobacter baumanii (patient 4), and penicillin-susceptible Streptococcus pneumonia (patient 10).
¶Of the 3 patients, 1 was infected with carbapenem-resistant P. aeruginosa (patient 3) and 1 was infected with carbapenem-resistant A. baumanii (patient 4).

Main Article

1Presented in part at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 Sep 12–15; Boston, Massachusetts, USA (late-breaker posters session, abstract V-448c).

Page created: July 25, 2011
Page updated: July 25, 2011
Page reviewed: July 25, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external